Patents by Inventor George T. Topalov

George T. Topalov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activators
    Patent number: 12351559
    Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
    Type: Grant
    Filed: October 20, 2023
    Date of Patent: July 8, 2025
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Lynn Resnick, George T. Topalov, Justin K. Belardi, James S. Hale, Scott S. Harried, Charles A. Flentge, David A. Mareska
  • KV7 channel activators compositions and methods of use
    Patent number: 12286408
    Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
    Type: Grant
    Filed: June 20, 2023
    Date of Patent: April 29, 2025
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Michael E. Bozik, Scott S. Harried, Lynn Resnick, George T. Topalov, Justin K. Belardi, Charles A. Flentge, David A. Mareska, James S. Hale
  • PYRAZOLO[1,5-A]PYRIDIN-2,3-YL AMIDES AS KV7 CHANNEL ACTIVATORS
    Publication number: 20250066351
    Abstract: Compounds such as those represented by Formula I can be potent for the Kv7.2/7.3 heteromultimer. These compounds may be used to treat a number of medical conditions, and may be included in dosage forms, pharmaceutical compositions, or medicaments.
    Type: Application
    Filed: January 6, 2023
    Publication date: February 27, 2025
    Inventors: Lynn RESNICK, Justin K. BELARDI, Charles A. FLENTGE, David A. MARESKA, George T. TOPALOV, Steven A. BOYD, James S. HALE
  • BENZOMIDAZOL-1,2-YL AMDES AS Kv7 CHANNEL ACTIVATORS
    Publication number: 20240300903
    Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
    Type: Application
    Filed: October 20, 2023
    Publication date: September 12, 2024
    Inventors: Lynn RESNICK, George T. TOPALOV, Justin K. BELARDI, James S. HALE, Scott S. HARRIED, Charles A. FLENTGE, David A. MARESKA
  • KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE
    Publication number: 20240002349
    Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
    Type: Application
    Filed: June 20, 2023
    Publication date: January 4, 2024
    Inventors: Michael E. BOZIK, Scott S. HARRIED, Lynn RESNICK, George T. TOPALOV, Justin K. BELARDI, Charles A. FLENTGE, David A. MARESKA, James S. HALE
  • Benzoimidazol-1,2-yl amides as Kv7 channel activators
    Patent number: 11834418
    Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: December 5, 2023
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Lynn Resnick, George T. Topalov, Justin K. Belardi, James S. Hale, Scott S. Harried, Charles A. Flentge, David A. Mareska
  • Kv7 channel activators compositions and methods of use
    Patent number: 11724990
    Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
    Type: Grant
    Filed: January 7, 2022
    Date of Patent: August 15, 2023
    Assignee: Biohaven Therapeutics Ltd.
    Inventors: Michael E. Bozik, Scott S. Harried, Lynn Resnick, George T. Topalov, Justin K. Belardi, Charles A. Flentge, David A. Mareska, James S. Hale
  • KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE
    Publication number: 20230000831
    Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
    Type: Application
    Filed: January 7, 2022
    Publication date: January 5, 2023
    Inventors: Michael E. BOZIK, Scott S. HARRIED, Lynn RESNICK, George T. TOPALOV, Justin K. BELARDI, Charles A. FLENTGE, David A. MARESKA, James S. HALE
  • KV7 channel activators compositions and methods of use
    Patent number: 11261162
    Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: March 1, 2022
    Assignee: KNOPP BIOSCIENCES, LLC
    Inventors: Michael E. Bozik, Scott S. Harried, Lynn Resnick, George T. Topalov, Justin K. Belardi, Charles A. Flentge, David A. Mareska, James S. Hale
  • BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS
    Publication number: 20210188782
    Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
    Type: Application
    Filed: December 18, 2020
    Publication date: June 24, 2021
    Inventors: Lynn RESNICK, George T. TOPALOV, Justin K. BELARDI, James S. HALE, Scott S. HARRIED, Charles A. FLENTGE, David A. MARESKA
  • KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE
    Publication number: 20210130299
    Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
    Type: Application
    Filed: October 22, 2020
    Publication date: May 6, 2021
    Inventors: Michael E. BOZIK, Scott S. HARRIED, Lynn RESNICK, George T. TOPALOV, Justin K. BELARDI, Charles A. FLENTGE, David A. MARESKA, James S. HALE
  • Benzoimidazol-1,2-yl amides as Kv7 channel activators
    Patent number: 10906877
    Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: February 2, 2021
    Assignee: Knopp Biosciences LLC
    Inventors: Lynn Resnick, George T. Topalov, Justin K. Belardi, James S. Hale, Scott S. Harried, Charles A. Flentge, David A. Mareska
  • Kv7 channel activators compositions and methods of use
    Patent number: 10851067
    Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: December 1, 2020
    Assignee: Knopp Biosciences LLC
    Inventors: Michael E. Bozik, Scott S. Harried, Lynn Resnick, George T. Topalov, Justin K. Belardi, Charles A. Flentge, David A. Mareska, James S. Hale
  • Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
    Patent number: 10669269
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: June 2, 2020
    Assignee: Array BioPharma Inc.
    Inventors: Mark Laurence Boys, Robert Kirk DeLisle, Erik James Hicken, April L. Kennedy, David A. Mareska, Fredrik P. Marmsäter, Mark C. Munson, Brad Newhouse, Bryson Rast, James P. Rizzi, Martha E. Rodriguez, George T. Topalov, Qian Zhao
  • BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS
    Publication number: 20200062714
    Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
    Type: Application
    Filed: October 31, 2017
    Publication date: February 27, 2020
    Inventors: Lynn RESNICK, George T. TOPALOV, Justin K. BELARDI, Charles A. FLENTGE, James S. HALE, David A. MARESKA
  • Imidazo[4,5-b]pyridin-2-yl amides as Kv7 channel activators
    Patent number: 10526328
    Abstract: Compounds represented by formula 1 can be potent and/or partially selective for the Kv7.2/7.3 heteromultimer. They may be useful in treating disorders related to seizures, pain, neurotransmitter release, etc.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: January 7, 2020
    Assignee: Knopp Biosciences LLC
    Inventors: Lynn Resnick, George T. Topalov, Charles A. Flentge, James S. Hale, David A. Mareska, Justin K. Belardi, Kai Zhang, Scott S. Harried
  • BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS
    Publication number: 20200002292
    Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
    Type: Application
    Filed: July 2, 2019
    Publication date: January 2, 2020
    Inventors: Lynn RESNICK, George T. TOPALOV, Justin K. BELARDI, James S. HALE, Scott S. HARRIED, Charles A. FLENTGE, David A. MARESKA
  • KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE
    Publication number: 20190284142
    Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.
    Type: Application
    Filed: March 19, 2019
    Publication date: September 19, 2019
    Inventors: Michael E. BOZIK, Scott S. HARRIED, Lynn RESNICK, George T. TOPALOV, Justin K. BELARDI, Charles A. FLENTGE, David A. MARESKA, James S. HALE
  • Benzoimidazol-1,2-yl amides as Kv7 channel activators
    Patent number: 10385025
    Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: August 20, 2019
    Assignee: Knopp Biosciences LLC
    Inventors: Lynn Resnick, George T. Topalov, Justin K. Belardi, James S. Hale, Scott S. Harried, Charles A. Flentge, David A. Mareska
  • IMIDAZO[4,5-B]PYRIDIN-2-YL AMIDES AS KV7 CHANNEL ACTIVATORS
    Publication number: 20190002464
    Abstract: Compounds represented by formula 1 can be potent and/or partially selective for the Kv7.2/7.3 heteromultimer. They may be useful in treating disorders related to seizures, pain, neurotransmitter release, etc.
    Type: Application
    Filed: September 7, 2018
    Publication date: January 3, 2019
    Inventors: Lynn RESNICK, George T. TOPALOV, Charles A. FLENTGE, James S. HALE, David A. MARESKA, Justin K. BELARDI, Kai ZHANG, Scott S. HARRIED